Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
COSMOS PharmaceuticalCSMYF 93 Earnings Yield (Joel Greenblatt) % is 7.59% as of Feb. 2026, which is 25% above its 10-year median of 6.08. GuruFocus rates CSMYF with a GF Score™ of 93/100 and a GF Value™ of $47.59 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 689 Healthcare Providers & Services companies, COSMOS Pharmaceutical ranks better than 78.37% on this metric.
COSMOS Pharmaceutical's Enterprise Value for the quarter that ended in Feb. 2026 was $3,954 Mil.
COSMOS Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Feb. 2026 was $292 Mil. COSMOS Pharmaceutical's Earnings Yield (Joel Greenblatt) for the quarter that ended in Feb. 2026 was 7.59%.
The historical rank and industry rank for COSMOS Pharmaceutical's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
CSMYF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 4.2 Med: 6.08 Max: 9.01
Current: 8.35
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of COSMOS Pharmaceutical was 9.01%. The lowest was 4.20%. And the median was 6.08%.
CSMYF's Earnings Yield (Joel Greenblatt) % is ranked better than 78.37% of 689
companies
in the Healthcare Providers & Services industry
Industry Median: 3.31
vs CSMYF: 8.35
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. COSMOS Pharmaceutical's Forward Rate of Return (Yacktman) % for the quarter that ended in Feb. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
COSMOS Pharmaceutical Earnings Yield (Joel Greenblatt) % Related Terms
COSMOS Pharmaceutical Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for COSMOS Pharmaceutical's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, COSMOS Pharmaceutical's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
COSMOS Pharmaceutical Earnings Yield (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, COSMOS Pharmaceutical's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where COSMOS Pharmaceutical's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
COSMOS Pharmaceuticals Earnings Yield (Joel Greenblatt) for the fiscal year that ended in May. 2026 is calculated as
COSMOS Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $292 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 7.59% mean?
COSMOS Pharmaceutical (CSMYF) has a Earnings Yield (Joel Greenblatt) % of 7.59% as of Feb. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on COSMOS Pharmaceutical and its competitors. This is 25% above median its historical median of 6.08. Over the past decade, COSMOS Pharmaceutical's Earnings Yield (Joel Greenblatt) % has ranged from 4.20 to 9.01. According to the industry distribution chart, COSMOS Pharmaceutical ranks #149 out of 689 companies in the Healthcare Providers & Services industry, placing it in the top 21.6%.
Is COSMOS Pharmaceutical's Earnings Yield (Joel Greenblatt) % too high?
COSMOS Pharmaceutical's current Earnings Yield (Joel Greenblatt) % of 7.59% is 25% above median its 10-year median of 6.08. Over the past 10 years, this metric has ranged from a low of 4.20 to a high of 9.01. The Healthcare Providers & Services industry median Earnings Yield (Joel Greenblatt) % is 3.31. COSMOS Pharmaceutical's value of 7.59% is 129.3% above this industry median. Based on the distribution chart, COSMOS Pharmaceutical ranks #149 out of 689 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, COSMOS Pharmaceutical has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does COSMOS Pharmaceutical's Earnings Yield (Joel Greenblatt) % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, COSMOS Pharmaceutical ranks #149 out of 689 companies for Earnings Yield (Joel Greenblatt) %. This places COSMOS Pharmaceutical in the top 22% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 3.31. COSMOS Pharmaceutical's value of 7.59% is 129.3% above this benchmark. Historically, COSMOS Pharmaceutical's own Earnings Yield (Joel Greenblatt) % has ranged from 4.20 to 9.01 over the past decade. While the company's 10-year median is 6.08 vs. the industry median of 3.31, COSMOS Pharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median Earnings Yield (Joel Greenblatt) % among Healthcare Providers & Services companies is 3.31, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. COSMOS Pharmaceutical's current Earnings Yield (Joel Greenblatt) % of 7.59% is 129.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on COSMOS Pharmaceutical and its competitors. For the Healthcare Providers & Services industry, the median Earnings Yield (Joel Greenblatt) % is 3.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. COSMOS Pharmaceutical's current Earnings Yield (Joel Greenblatt) % is 7.59%, which is 25% above median its own 10-year median of 6.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is COSMOS Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, COSMOS Pharmaceutical (CSMYF) is currently considered Modestly Undervalued. The stock's GF Value™ is $47.59, compared to a current price of $37.06 — trading 22.1% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 7.59%, which is 25% above median its 10-year median of 6.08 and 129.3% above the Healthcare Providers & Services industry median of 3.31. COSMOS Pharmaceutical's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For COSMOS Pharmaceutical (CSMYF), the current Earnings Yield (Joel Greenblatt) % is 7.59% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is COSMOS Pharmaceutical (CSMYF) Overvalued in 2026?
Based on GuruFocus' analysis, COSMOS Pharmaceutical stock appears to be undervalued.
The current stock price of $37.06 is trading 22.1% below its estimated GF Value™ of $47.59.
GuruFocus considers COSMOS Pharmaceutical to be Modestly Undervalued.
Key valuation signals for CSMYF:
Earnings Yield (Joel Greenblatt) %: 7.59% (25% above median its 10-year median of 6.08)
GF Value™: $47.59 vs. price of $37.06 (22.1% below fair value)
Industry Position: 129.3% above the Healthcare Providers & Services median (#149 of 689)
No single metric tells the full story. See the CSMYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company's revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.
93GF Score
Get the complete analysis for CSMYF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSMYF has been successfully added to your 
